Axsome Therapeutics (AXSM) Misses Q4 EPS by 92c

Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($2.08), $0.92 worse than the analyst estimate of ($1.16). Revenue for the quarter came in at $71.53 million versus the consensus estimate of $68.83 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Oracle raises full year profit guidance, stock rises after hours
• Adobe beats Q3 targets, but soft Q4 sales guidance triggers dip